Derek Lowe

1 story

Merck Moderna Melanoma Therapy Shows 42% Lower Recurrence Risk
Merck and Moderna's melanoma combo therapy cuts recurrence risk by 42% in Phase 3 trial.
Seekingalpha · 1m